CV
Dr. med. Grit S. Herter-Sprie
Academic education
10/2003 - 11/2008: Albert Ludwigs University of Freiburg, School of Medicine
10/2001 - 09/2003: Albert Ludwigs University of Freiburg, School of Dentistry
Scientific degrees
08/2011: Standard Educational Commission for Foreign Medical Graduates Certificate
11/2008: M.D., Medical School, Albert Ludwigs University of Freiburg, Summa cum Laude: “Untersuchungen zur Funktion von SecA bei der Integration von Membranproteinen in Escherichia coli” (Supervisor: Hans-Georg Koch, PhD, Institute of Biochemistry and Molecular Biology, Albert Ludwigs University of Freiburg, Department Head: Nikolaus Pfanner, M.D.)
11/2008: Graduation from Medical School, Albert Ludwigs University of Freiburg
Scientific/professional career
08/2018 - present: Junior principal investigator, Department I for Internal Medicine, Hematology/Oncology, University Hospital Cologne (associated with H. Christian Reinhardt, M.D.)
09/2015 - present: Medical Resident, Department I for Internal Medicine, Hematology/Oncology, University Hospital Cologne (Department Head: Michael Hallek, M.D.)
05/2012 - 06/2015: Postdoctoral Research Fellow, Dana-Farber Cancer Institute, Boston, USA (with Kwok-Kin Wong, M.D.,PhD)
07/2010 - 04/2012: Postdoctoral Research Fellow, Max Planck Institute and Cologne Center for Genomics, University of Cologne (with H. Christian Reinhardt, M.D.)
01/2009 - 04/2012: Medical Resident, Department I for Internal Medicine, Hematology/Oncology, University Hospital Cologne (Department Head: Michael Hallek, M.D.)
Awards and Fellowships
01/2019 - 12/2021: Research grant Deutsche Forschungsgemeinschaft
01/2019 - 12/2019: Gusyk position – support for clinical scientists with family duties, University of Cologne
01-06/2016: CECAD Gerok position for young clinicians, University of Cologne
01-06/2017: CECAD - Cluster of Excellence (paused for parental leave)
10/2014 - 09/2015: Barr Award of Claudia Adams Barr Program for Innovative Cancer Research
02/2013 - 01/2015: Research fellowship Deutsche Forschungsgemeinschaft
07/2010 - 12/2011: Research fellowship Köln Fortune Program
10 most relevant publications
- Torgovnick A, Heger JM, Liaki V, Isensee J, Schmitt A, Knittel G, Riabinska A, Beleggia F, Laurien L, Leeser U, Jüngst C, Siedek F, Vogel W, Klümper N, Nolte H, Wittersheim M, Tharun L, Castiglione R, Krüger M, Schauss A, Perner S, Pasparakis M, Büttner R, Persigehl T, Hucho T*, Herter-Sprie GS*, Schumacher B*, Reinhardt HC*. The Cdkn1aSUPER mouse as a tool to study p53-mediated tumor suppression. Cell Reports. 2018 Oct 23; 25:1027. *equal contribution
- Herter-Sprie GS*, Koyama S*, Korideck H, Hai J, Deng J, Li YY, Buczkowski KA, Grant AK, Ullas S, Rhee K, Cavanaugh JD, Poudel Neupane N, Christensen CL, Herter JM, Makrigiorgos GM, Hodi FS, Freeman GJ, Dranoff G, Hammerman PS, Kimmelman AC, Wong KK. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016 Jun 16;1(9):e87415. *equal contribution
- Herter-Sprie GS, Korideck H, Christensen CL, Herter JM, Rhee K, Berbeco RI, Bennett DG, Akbay EA, Kozono D, Mak RH, Makrigiorgos GM, Kimmelman AC, Wong KK. Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. Nat Commun. 2014 18;5:5870.
- Koyama S, Akbay EA, Li Y, Herter-Sprie GS, Buczkowski KA, Williams R, Gandhi L, Redig A, Rodig SJ, asahina H, Jones RE, Kulkarni MM, Fecci PE, Johnson BE, Janne PA, Engelman J, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS. Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint. Nat Commun. 2016 Feb 17;7:10501.
- Koyama S, Akbay EA, Li Y, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra ER, Wistuba II, Soucheray M, Thai TC, Asahina H, Kitajima S, Altabef A, Cavanaugh JD, Rhee K, Gao P, Zhang H, Fecci PE, Shimamura T, Hellmann MD, Heymach JV, Hodi FS, Freeman GJ, Barbie DA, Dranoff G, Hammerman PS, Wong KK. Loss of STK11/LKB1 drives production of pro-inflammatory cytokines and T cell suppression in the lung cancer immune microenvironment. Cancer Res. 2016 Feb 1, 76(5).
- Herter JM, Grabie N, Cullere X, Azcutia V, Rosetti F, Bennett P, Herter-Sprie GS, Elyaman W, Luscinskas FW, Lichtman AH, Mayadas TN. AKAP9 regulates activation-induced T lymphocyte retention at sites of inflammation. Nat Commun. 2015 Dec 18;6:10182.
- Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cananaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA, Bradner JE, George RE, Gray NS, Young RA, Wong KK. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014. 8;26(6):909-22.
- Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, Herter-Sprie GS, Akbay EA, Tchaicha JH, Altabef A, Reibel JB, Walton Z, Ji H, Watanabe H, Jänne PA, Castrillon DH, Rustgi AK, Bass AJ, Freeman GJ, Padera RF, Dranoff G, Hammerman PS, Kim CF, Wong KK. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014, 12;25(5): 590-604.
- Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK, Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas J, Chen S, Reinhardt HC. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med. 2013, 12;5(189) 189a78.
- Deitermann S*, Sprie GS*, Koch HG. A dual function for SecA in the assembly of single spanning membrane proteins in Escherichia coli. J Biol Chem. 2005, 25;280(47): 39077-85.
*equal contribution
Contact Information
Dr. med. Grit S. Herter-Sprie
Junior Research Group Leader and Medical Resident
University Hospital of Cologne
Department I for Internal Medicine, Hematology/Oncology, Center for Molecular Medicine (CMMC)
